Market capitalization | JPY6.91t |
Enterprise Value | JPY6.37t |
P/E (TTM) P/E ratio | 23.74 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.38 |
P/S ratio (TTM) P/S ratio | 3.66 |
P/B ratio (TTM) P/B ratio | 4.26 |
Dividend yield | 2.11% |
Last dividend (FY26) | JPY78.00 |
As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.
16 Analysts have issued a DAIICHI SANKYO forecast:
16 Analysts have issued a DAIICHI SANKYO forecast:
Mar '25 |
+/-
%
|
||
Revenue | 1,886,256 1,886,256 |
18%
18%
|
|
Gross Profit | 1,470,459 1,470,459 |
24%
24%
|
|
EBITDA | 371,943 371,943 |
53%
53%
|
EBIT (Operating Income) EBIT | 303,294 303,294 |
65%
65%
|
Net Profit | 295,756 295,756 |
47%
47%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Hiroyuki Okuzawa |
Founded | 2005 |
Website | www.daiichisankyo.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.